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Aims: Glucagon-like peptide 1 (GLP-1) is an insulin secretagogue, released in response to meal ingestion and
efﬁciently lowers blood glucose in Type 2 diabetic patients. GLP-1(7-36) is rapidly metabolized by dipeptidyl
peptidase IV to the major metabolite GLP-1(9-36)-amide, often thought to be inactive. Inhibitors of this enzyme
arewidely used to treat diabetes. Our aimwas to characterize the binding of GLP-1(9-36) to nativemouse tissues
and to cells expressing GLP1-R as well as to measure functional responses in the mouse aorta compared with
GLP-1(7-36).
Main methods: The afﬁnity of [125I]GLP-1(7-36) and [125I]GLP-1(9-36) was measured in mouse tissues by
saturation binding and autoradiography used to determine receptor distribution. The afﬁnity of both peptides
was compared in binding to recombinant GLP-1 receptors using cAMP and scintillation proximity assays.
Vasoactivity was determined in mouse aortae in vitro.
Key ﬁndings: In cells expressing GLP-1 receptors, GLP-1(7-36) bound with the expected high afﬁnities (0.1 nM)
and an EC50 of 0.07 nM in cAMP assays but GLP-1(9-36) bound with 70,000 and 100,000 fold lower afﬁnities
respectively. In contrast, in mouse brain, both labeled peptides bound with a single high afﬁnity, with Hill
slopes close to unity, although receptor density was an order of magnitude lower for [125I]GLP-1(9-36). In
functional experiments both peptides had similar potencies, GLP-1(7-36), pD2 = 7.40 ± 0.24 and GLP-1(9-36),
pD2 = 7.57 ± 0.64.
Signiﬁcance: These results suggest that GLP-1(9-36) binds and has functional activity in the vasculature but these
actions may be via a pathway that is distinct from the classical GLP-1 receptor and insulin secretagogue actions.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
Glucagon-like peptide 1 (GLP-1) is derived from the transcription
product of the proglucagon genesis, synthesized in the intestine,
released in response to meal ingestion and efﬁciently lowers blood
glucose in Type 2 diabetic patients. The GLP-1R (glucagon-like
peptide-1 receptor) controls the physiological response to GLP-1 and
is currently a major target for the development of drugs owing to the
broad range of potential beneﬁcial effects in Type 2 diabetes (Koole
et al., 2013)., University of Cambridge, Level
ke's Hospital, Cambridge CB2
.
nport).
. This is an open access article underGLP-1(7-36) is the biologically active form and has a very short half-
life. It is rapidly metabolized by dipeptidyl peptidase IV (DPP-4) to the
major metabolite GLP-1(9-36)-amide, (Knudsen and Pridal, 1996)
which comprises about 60% of circulating GLP peptides and thought to
be the major route of inactivation. Inhibitors of DPP-4 enzyme are
widely used to treat diabetes.
GLP-1(9-36) is often thought to be inactive. However, in obesemice
acute administration of GLP-1(9-36) potently inhibits hepatic glucose
production with a similar effect in lean mice in the presence of GLP-1
antagonist, exendin (9-39) (Elahi et al., 2008). This anti-diabetogenic
action of GLP-1(9-36) may have a therapeutic beneﬁt. In addition, vas-
cular actions of GLP-1(7-36) and GLP-1(9-36) have been reported in
rodent arterieswith comparable potency. These actions include changes
in coronary ﬂow in isolated mouse hearts in both wild-type and
Glp1r(−/−) mice deﬁcient in GLP1-R (Ban et al., 2008), vasorelaxation
in rat femoral artery (Nystrom et al., 2005) and in rat aorta (Green et al.,the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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to explore further similarities (or differences) in the potency of the two
peptides. Based on previous studies above, we hypothesized that GLP-
1(9-36) would have similar potency to GLP-1(7-36).
It is unclear to what extent GLP-1(9-36)mediates functional activity
via the GLP1-R or by other previously uncharacterized receptors. Our
aim was to characterize the binding of the novel ligand [125I]GLP-1(9-
36) in tissues from mouse and to determine the pharmacodynamic
parameters (equilibrium dissociation constant, KD and receptor density,
BMAX) compared with [125I]GLP-1(7-36). Secondly, cell lines artiﬁcially
expressing GLP1-R were used in scintillation proximity and second
messenger cAMP assays to compare the binding of unlabeled GLP-1(7-
36) and GLP-1(9-36). Our ﬁnal aim was to compare functional
responses of both peptides in mouse aorta.Materials and methods
[125I]GLP-1(7-36) and [125I]GLP-1(9-36) were both custom synthe-
sized byAnawaTrading SA, Switzerland, using the Chloramine Tmethod,
typical speciﬁc activity ~ 2175 Ci/mmol (for scintillation proximity
assays [125I]GLP-1(7-36)was fromPerkin Elmer), scintillation proximity
assay beads were from Life Technologies and cAMP assays were from
CISBIO. All peptides were synthesized by Pﬁzer Cambridge, MA, U.S.A.Mouse tissue samples
The procedures used in this studywere approved by the local animal
ethical committee and were performed under the UK Home Ofﬁce
Project Licence authority; the study conformed to the National Insti-
tutes of Health Guidelines for the Care and Use of Laboratory Animals.
Adult mice, C57/BL6J (either sex, 25–35 g); were killed with CO2 and
the brain and aorta were removed prior to binding and functional
experiments.Table 1
Characterization of peptides in native tissue and recombinant GLP-1 receptors.
Saturation binding assay






[125I]GLP-1(7-36) 1.29 ± 0.26 57.0 ± 14.5 0.96 ± 0.06



































Saturation binding assays were carried out adaptingmethods previ-
ously described (Maguire et al., 2012), to determine the afﬁnity (KD)
and binding density (BMAX) of two custom synthesized ligands [125I]
GLP-1(7-36) or [125I]GLP-1(9-36).
Coronal and sagittal sections of the brain containing thehypothalamus
and thalamus, regions which have the highest density of mRNA
encoding GLP-1 receptor were selected for this study (Allen Brain
Atlas, 2008; Regard et al., 2008).
Brieﬂy, 10 μm cryostat-cut sections (Bregma ~ −0.7 to −1.0) of
adult mouse brain were pre-incubated at room temperature for
20 min in binding buffer (25 mM Hepes, 2 mM MgCl2, 0.05% Tween-
20, 0.2% BSA, 0.01% Bacitracin, pH 7.4) prior to incubation for 90 min
in buffer containing increasing concentrations of either [125I]GLP-1(7-
36) or [125I]GLP-1(9-36) (4 pM–4 nM) at room temperature. Nonspeciﬁc
binding was determined in adjacent sections using 10 μM of the
relevant unlabeled GLP-1(7-36) and GLP-1(9-36) (human, rat, mouse)
peptides.
Sections were washed (4 × 30 s in 50mMTris–HCl at 4 °C) to break
equilibrium and counted in a gamma counter. Saturation binding curves
from replicate experiments were co-analyzed using the KELL suite of
programs (Biosoft, Cambridge, UK), and values of pooled KD and BMAX
were expressed as mean ± S.E.M.
Autoradiography was carried out as above with a ﬁxed concentra-
tion (0.2 nM) of each radioligand in a set of adjacent sections to deter-
mine total binding and with the addition of either relevant unlabeled
peptide GLP-1(7-36) or GLP-1(9-36) at 10 μM for non-speciﬁc binding.
Slides were rinsed in de-ionized water dried in a cold-air stream and
apposed to a Kodak MR-1 ﬁlm for 3 days prior to hand processing.Scintillation proximity assays in cells expressing GLP-1R
Tomeasure the ability of both GLP-1(7-36) and (9-36) to bind to the
GLP-1R, and therefore have the potential to mimic GLP-1 activity,
radioligand displacement assays were performed in membranes pre-
pared from CHO cells expressing the hGLP-1R. Unlabeled Exendin-4 at
a ﬁnal concentration of 1 μMwas used to determine non-speciﬁc bind-
ing. Afﬁnity was expressed as a Ki value, deﬁned as the concentration of
compound required to decrease [125I]GLP-1(7-36) binding by 50% for
a speciﬁc membrane batch at a given concentration of radioligand. The
Ki for [125I]-GLP-1(7-36) was determined by carrying out saturation
binding, with data analysis by non-linear regression, ﬁt to a one-site
hyperbola (Graph Pad Prism). IC50 determinations were made from
competition curves, analyzed with a proprietary curve ﬁtting program
(SIGHTS) and a 4-parameter logistic dose response equation. Afﬁnity
constants were calculated from IC50 values, using the Cheng-Prusoff
equation and results were given as mean and conﬁdence interval.
cAMP assays in cells expressing GLP-1R
GLP-1 agonist activity was determined with a cell-based functional
assay utilizing an HTRF (Homogeneous Time-Resolved Fluorescence)
cAMP detection kit (cAMP dynamic 2 Assay Kit) a competitive immuno-
assay that measures cAMP levels in the human GLP-1 CHO-K1 cell line
expressing wild type GLP-1R receptors. Fluorescence was read with an
Envision 2104 multi-label plate reader using an excitation of 330 nm
and emissions of 615 and 665 nm. Raw data were converted to nM
cAMP by interpolation from a cAMP standard curve, and EMAX and
EC50 determinations were made from an agonist-response curve
analyzed with a curve ﬁtting program using a 4-parameter logistic
dose response equation using Graphpad Prism.
In vitro pharmacology — wire myography in mouse aorta
In functional experiments, thoracic mouse aortae (endothelium
intact) were mounted in wire myographs and the effect of increasing
concentrations of each peptide was measured. Rings of aorta (b2 mm
in length)were dissected andmounted inwiremyographs formeasure-
ment of isometric tension, as previously described (Maguire et al., 2009,
2011, 2014). The segments were bathed in oxygenated Krebs' solution
at 37 °C and were set to 90% of the internal diameter at 100 mm Hg.
Maximal force (mN mm−1) was measured three times with a
potassium-rich Krebs' solution (100 mM) at 15-min intervals before
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tides (0.1 nM–300 nM). Concentration response curves were expressed
as a percentage of the mean of the response to 100 mM KCl. They were
analyzed using a 4-parameter logistic equation usingGraphpad Prism to
obtain values of molar concentration producing 50% of the maximum
response (EC50) andmaximum responsewas expressed as a percentage
of the mean response to 100 mM KCl (EMAX). Potency values were
normalized by logarithmic transformation to pD2 values (− log10
EC50). Selected aortae were also tested for vasodilatation by pre-
constriction with 10 μM phenylephrine 1 and concentration response
curves were tested using the two GLP peptides. Experiments were
terminated by 10 μM SNAP to conﬁrm that all vessels tested were
capable of vasodilatation. The purpose was to show that the lack of
vasodilator response to GLP agonists was not a consequence of a lack
of ability to relax.Fig. 1. Autoradiograph showing localization of speciﬁc binding for both [125I]GLP-1(7-36) and [1
tions showing speciﬁc binding of [125I]GLP-1(7-36) in molecular layer of the cerebellum (c), h
speciﬁc binding in (C only) hippocampus (h), thalamus (t) and hypothalamus (ht). E and F. Co
binding (NSB) was determined in adjacent sections using an excess (10 μM) of the relevant unResults
Radioligand binding
Saturation binding studies in adjacent coronal sections ofmouse brain
containing the hypothalamus and thalamuswhich have the highest den-
sity ofmRNA encoding GLP-1R (Regard et al., 2008) showed both labeled
peptides bound with a single high afﬁnity, with Hill slopes close to unity
(Table 1). However, the density of receptors was an order of magnitude
lower for [125I]GLP-1(9-36) in this native tissue. Autoradiography using
sagittal (Fig. 1A andB) and coronal sections (Fig. 1C andD) demonstrated
speciﬁc binding of [125I]GLP-1(7-36) to the cerebellum (molecular layer),
hippocampus, thalamus and hypothalamus. In agreementwith the lower
density measured in the saturation binding assays, [125I]GLP-1(9-36)
bindingwasmainly conﬁned in coronal sections to the hippocampus (h).25I]GLP-1(9-36) ligands inmouse sagittal and coronal brain sections. A and B. Sagittal sec-
ippocampus (h), thalamus (t) and hypothalamus (ht). C and D. Coronal section showing
ronal section showing [125I]GLP-1(9-36) speciﬁc binding in hippocampus (h). Nonspeciﬁc
labeled GLP-1(7-36) and GLP-1(9-36) (human, rat, mouse) peptides. (Scale bar = 5 mm).
Table 2
In vitro pharmacology of mouse aorta. Both GLP-1(7-36) and GLP-1(9-36) caused
vasoconstriction with similar potencies. There was no evidence for endothelium depen-









7.40 ± 0.24 34 ± 8%
GLP-1(9-36)
(n = 3)
7.57 ± 0.64 25 ± 7%
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Scintillation proximity assay using GLP-1R artiﬁcially expressed in
cell lines demonstrated a marked difference between the two GLP-1
peptides. GLP-1(7-36) bound with the expected afﬁnity (0.1 nM)
whereas GLP-1(9-36) bound with a 70, 000 fold lower afﬁnity than in
the radiolabeled binding assay (Table 2).
cAMP assays
Similarly, in cAMP assays using GLP-1R artiﬁcially expressed cell
lines, GLP-1(7-36) gave an expected EC50 of 0.07 nM whereas GLP-
1(9-36) produced a 100,000 fold lower EC50 in the cAMP assay, with a
maximum response of b10% (Table 2).
In vitro pharmacology — wire myography
In functional myography experiments in mouse aortae both pep-
tides caused vasoconstriction with similar potencies (Fig. 2, Table 1).
There was no evidence for endothelium dependent vasodilatation
following pre-constriction with phenylephrine (10 μM, n = 3).
Discussion
This study has shown that both [125I]GLP-1(7-36) and [125I]GLP-1(9-
36) bound with a single high afﬁnity, with Hill slopes close to unity,
although the density of [125I]GLP-1(9-36) binding was an order of
magnitude lower.
Intriguingly, we found in scintillation proximity and cAMP assays
using GLP1-R receptors artiﬁcially expressed in cell lines that, while
GLP-1(7-36) bound with the expected afﬁnities, GLP-1(9-36) bound
with a 70,000 fold lower afﬁnity in the SPA binding assay, and a
100,000 fold lower EC50 in cAMP, with a maximum response of b10%.
These results are concordant with studies in cells expressing rat


















Fig. 2. Graph showing the concentration–response curve for the vascular actions of GLP
peptides inmouse aorta. Both peptides caused vasoconstriction and had similar potencies.
(Values are mean 3–6 individuals ± SEM).Pridal, 1996), where these receptors were also reported to have low
afﬁnity for GLP-1(9-36). In addition, the cardioprotective actions of
GLP-1(9-36) were preserved in cardiomyocytes isolated from GLP-1R
knock-out mice (Ban et al., 2010).
In a detailed study of forty-two mouse tissues measuring mRNA
encoding the GLP-1R by qRT-PCR, Regard et al. (2008) found that
expression of the receptor was very limited, with the highest levels in
the pancreas and islets of Langerhans, as expected from the known
actions of the peptide, with lower levels in the lung, stomach and
brain. We choose to study mouse aorta, as messenger RNA (Regard
et al., 2008) was not detected in this tissue and this strongly suggested
that the actions of both peptides were unlikely to be via the GLP-1R. In
agreement, in functional myography experiments in mouse aortae both
peptides caused vasoconstriction with similar potencies.
Previous studies have shown that the action of GLP-1(7-36) in the
rodent vasculature is complex with both constrictor responses as
shown here for mouse aorta, as well as endothelium dependent and
independent vasodilator responses. In chronically instrumented rats
in vivo, infusion of GLP-1(7-36) had regional hemodynamic effects
comprising tachycardia, a rise in blood pressure, renal and mesenteric
vasoconstriction but hindquarters vasodilatation (Gardiner et al.,
2010). In isolated rat arteries in vitro, where metabolism would be
expected to be minimized, GLP-1(7-36) causes both endothelium
dependent and independent relaxation (Richter et al., 1993; Golpon
et al., 2001; Ozyazgan et al., 2005; Nystrom et al., 2005; Green et al.,
2008; Nathanson et al., 2009). Importantly, where studies compared
both peptides, for example in rat aorta and femoral artery, GLP-1(9-
36) displays similar potency to GLP-1(7-36) (Green et al., 2008;
Nathanson et al., 2009) consistent with similar potency of the two
peptides inmouse aorta in this study albeit that the functional response
that we observed was vasoconstriction.
Taken together, these results show that GLP-1(9-36) can distinguish
between GLP-1R and a second, as yet unidentiﬁed receptor that may
mediate at least part of the vascular response to the two peptides. The
mechanism of action is not known but since the peptides produced
vasoconstriction, it may involve a number of possible actions such as
modulating intracellular calcium, but downstream signaling has not
been investigated. Interestingly, Shah et al. (2011) showed that that
endothelium-dependent vasorelaxation found in response to the DPP-
4 blocker, alogliptin was independent of GLP-1 pathways.
In regions of mouse brain known to express GLP-1R, [125I]GLP-1(9-
36) bound with similar afﬁnity but labeled a smaller population of
receptors than [125I]GLP-1(7-36). Taken together, these results suggest
interaction with a receptor distinct from GLP-1R.
There are four other members of the glucagon family of receptors
(glucagon-like peptide 2, growth hormone releasing hormone, gastric
inhibitory polypeptide and glucagon) but these all have a restricted dis-
tribution (Regard et al., 2008) and are not thought to be activated at
physiological concentrations by GLP-1 peptides. Both peptides were
present in a library of 10,000 ligands that were screened against
eighty-two remaining G-protein coupled receptors that have been pre-
dicted to exist in the human genome and designated as ‘orphan’ as the
endogenous ligand is not yet know. However, but no hits were identi-
ﬁed (Southern et al., 2013; Davenport et al., 2013).
Conclusion
The results suggest that GLP-1(9-36) has functional activity in the
vasculature at concentrations similar to those circulating levels in the
plasma. It is possible that the increased sensitivity to GLP-1(9-36) in
native tissue than in cells artiﬁcially expressing GLP-1R is the result of
interaction with other factors such as accessory proteins or formation
of heterodimers with other receptors not present in artiﬁcial cell lines.
A more intriguing possibility is that the vascular actions may be via a
pathway that is distinct from the classical GLP-1 receptor and insulin
secretagogue actions.
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